Burzynski Research
Long-term survival of high-risk pediatric patients with primitive
neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
Abstract
Primitive neuroectodermal tumors (PNETs) are
usually successfully treated with craniospinal radiation and chemotherapy;
however, difficulties with standard treatment can be encountered in very young
children, in adult patients at high risk of complication from standard
treatment, and in patients with recurrent tumors. Thirteen children, either
with recurrent disease or high risk, were treated in phase II studies with
antineoplastons (ANP). The median age of patients was 5 years, 7 months (range,
1-11). Medulloblastoma was diagnosed in 8 patients, pineoblastoma in 3
patients, and other PNET in 2 patients.
Previous treatments included surgery in 12 patients (1 had biopsy only, suboccipital craniotomy), chemotherapy in 6 patients, and radiation therapy in 6 patients. Six patients had not received prior chemotherapy or radiation. The treatment consisted of intravenous infusions of 2 formulations of ANP, A10 and AS2-1, and was administered for an average of 20 months. The average dosage of A10 was 10.3 g/kg/d and of AS2-1 was 0.38 g/kg/d. Complete response was accomplished in 23%, partial response in 8%, stable disease in 31%, and progressive disease in 38% of cases. Six patients (46%) survived more than 5 years from initiation of ANP; 5 were not treated earlier with radiation therapy or chemotherapy. The serious side effects included single occurrences of fever, granulocytopenia, and anemia. The study is ongoing and accruing additional patients. The percentage of patients' response is lower than for standard treatment of favorable PNET, but long-term survival in poor-risk cases and reduced toxicity makes ANP promising for very young children, patients at high risk of complication of standard therapy, and patients with recurrent tumors.
Previous treatments included surgery in 12 patients (1 had biopsy only, suboccipital craniotomy), chemotherapy in 6 patients, and radiation therapy in 6 patients. Six patients had not received prior chemotherapy or radiation. The treatment consisted of intravenous infusions of 2 formulations of ANP, A10 and AS2-1, and was administered for an average of 20 months. The average dosage of A10 was 10.3 g/kg/d and of AS2-1 was 0.38 g/kg/d. Complete response was accomplished in 23%, partial response in 8%, stable disease in 31%, and progressive disease in 38% of cases. Six patients (46%) survived more than 5 years from initiation of ANP; 5 were not treated earlier with radiation therapy or chemotherapy. The serious side effects included single occurrences of fever, granulocytopenia, and anemia. The study is ongoing and accruing additional patients. The percentage of patients' response is lower than for standard treatment of favorable PNET, but long-term survival in poor-risk cases and reduced toxicity makes ANP promising for very young children, patients at high risk of complication of standard therapy, and patients with recurrent tumors.
Stanislaw R. Burzynski, MD, PhD: novel cancer
research and the fight to prove its worth. Burzynski SR.
Altern Ther Health Med. 2012
May-Jun;18(3):54-61. No abstract available.
PMID: 22875562 [PubMed - indexed for MEDLINE]
Related citations
Select item 16484713
2.
Targeted therapy with antineoplastons A10 and
AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Burzynski SR, Janicki TJ, Weaver RA,
Burzynski B.
Integr Cancer Ther. 2006 Mar;5(1):40-7.
PMID: 16484713 [PubMed - indexed for MEDLINE]
Related citations
Select item 15911929
3.
Long-term survival of high-risk pediatric
patients with primitive neuroectodermal tumors treated with antineoplastons A10
and AS2-1.
Burzynski SR, Weaver RA, Janicki T,
Szymkowski B, Jurida G, Khan M, Dolgopolov V.
Integr Cancer Ther. 2005 Jun;4(2):168-77.
PMID: 15911929 [PubMed - indexed for MEDLINE]
Related citations
Select item 15563234
4.
Phase II study of antineoplaston A10 and
AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary
report.
Burzynski SR, Weaver RA, Lewy RI, Janicki TJ,
Jurida GF, Szymkowski BG, Khan MI, Bestak M.
Drugs R D. 2004;5(6):315-26.
PMID: 15563234 [PubMed - indexed for MEDLINE]
Related citations
Select item 15312271
5.
Long-term survival and complete response of a
patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
Burzynski SR, Lewy RI, Weaver R, Janicki T,
Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.
Integr Cancer Ther. 2004 Sep;3(3):257-61.
PMID: 15312271 [PubMed - indexed for MEDLINE]
Related citations
Select item 15035877
6.
Managing social conflict in complementary and
alternative medicine research: the case of antineoplastons.
Hammer MR, Jonas WB.
Integr Cancer Ther. 2004 Mar;3(1):59-65.
PMID: 15035877 [PubMed - indexed for MEDLINE]
Related citations
Select item 15035876
7.
The present state of antineoplaston research
(1).
Burzynski SR.
Integr Cancer Ther. 2004 Mar;3(1):47-58.
Review.
PMID: 15035876 [PubMed - indexed for MEDLINE]
Related citations
Select item 12718563
8.
Phase II study of antineoplaston A10 and
AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a
preliminary report.
Burzynski SR, Lewy RI, Weaver RA, Axler ML,
Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.
Drugs R D. 2003;4(2):91-101.
PMID: 12718563 [PubMed - indexed for MEDLINE]
Related citations
Select item 10814881
9.
Potential utility of antineoplaston A-10
levels in breast cancer.
Badria F, Mabed M, Khafagy W, Abou-Zeid L.
Cancer Lett. 2000 Jul 3;155(1):67-70.
PMID: 10814881 [PubMed - indexed for MEDLINE]
Related citations
Select item 10377942
10.
Efficacy of antineoplastons A10 and AS2-1.
Burzynski SR.
Mayo Clin Proc. 1999 Jun;74(6):641-2. No
abstract available.
PMID: 10377942 [PubMed - indexed for MEDLINE]
Related citations
Select item 8755117
11.
Inhibitory effect of antineoplaston A10 and
AS2-1 on human hepatocellular carcinoma.
Tsuda H, Iemura A, Sata M, Uchida M, Yamana
K, Hara H.
Kurume Med J. 1996;43(2):137-47.
PMID: 8755117 [PubMed - indexed for MEDLINE]
Free Article
Related citations
Select item 8535046
12.
Potential of antineoplastons in diseases of
old age.
Burzynski SR.
Drugs Aging. 1995 Sep;7(3):157-67. Review. No
abstract available.
PMID: 8535046 [PubMed - indexed for MEDLINE]
Related citations
Select item 7850766
13.
Cellular accumulation of antineoplaston AS21
in human hepatoma cells.
Sołtysiak-Pawłuczuk D, Burzyński SR.
Cancer Lett. 1995 Jan 6;88(1):107-12.
PMID: 7850766 [PubMed - indexed for MEDLINE]
Related citations
Select item 8667595
14.
Toxicological study on antineoplastons A-10
and AS2-1 in cancer patients.
Tsuda H, Hara H, Eriguchi N, Nishida H,
Yoshida H, Kumabe T, Sugita Y.
Kurume Med J. 1995;42(4):241-9.
PMID: 8667595 [PubMed - indexed for MEDLINE]
Free Article
Related citations
Select item 8529528
15.
The influence of antineoplaston A5 on
particular subtypes of central dopaminergic receptors.
Juszkiewicz M, Chodkowska A, Burzynski SR,
Mlynarczyk M, Kleinrok Z.
Drugs Exp Clin Res. 1995;21(4):153-6.
PMID: 8529528 [PubMed - indexed for MEDLINE]
Related citations
Select item 7813388
16.
The influence of antineoplaston A5 on the
central dopaminergic structures.
Juszkiewicz M, Chodkowska A, Burzynski SR,
Feldo M, Majewska B, Kleinrok Z.
Drugs Exp Clin Res. 1994;20(4):161-7.
PMID: 7813388 [PubMed - indexed for MEDLINE]
Related citations
Select item 2152694
17.
Treatment of hormonally refractory cancer of
the prostate with antineoplaston AS2-1.
Burzynski SR, Kubove E, Burzynski B.
Drugs Exp Clin Res. 1990;16(7):361-9.
PMID: 2152694 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569020
18.
Stereochemical modelling studies of the
interaction of antineoplaston A10 with DNA.
Hendry LB, Muldoon TG, Burzynski SR, Copland
JA, Lehner AF.
Drugs Exp Clin Res. 1987;13 Suppl 1:77-81.
PMID: 3569020 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569019
19.
Chemo-surveillance: a novel concept of the
natural defence mechanism against cancer.
Liau MC, Szopa M, Burzynski B, Burzynski SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:71-6.
PMID: 3569019 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569018
20.
Quantitative assay of plasma and urinary
peptides as an aid for the evaluation of cancer patients undergoing
antineoplaston therapy.
Liau MC, Szopa M, Burzynski B, Burzynski SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:61-70.
PMID: 3569018 [PubMed - indexed for MEDLINE]
N,N'-disubstituted L-isoglutamines as novel
cancer chemotherapeutic agents.
Khalid M, Burzynski SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:57-60.
PMID: 3569017 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569016
22.
Chemoprevention by antineoplaston A10 of
benzo(a)pyrene-induced pulmonary neoplasia.
Kampalath BN, Liau MC, Burzynski B, Burzynski
SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:51-5.
PMID: 3569016 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569015
23.
Pharmacokinetic study of radioactive
antineoplaston A10 following oral administration in rats.
Ashraf AQ, Liau MC, Kampalath BN, Burzynski
SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:45-50.
PMID: 3569015 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569014
24.
Phase I clinical studies of antineoplaston A5
injections.
Burzynski SR, Kubove E, Burzynski B.
Drugs Exp Clin Res. 1987;13 Suppl 1:37-43.
PMID: 3569014 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569013
25.
Tissue culture and animal toxicity studies of
antineoplaston A5.
Lee SS, Burzynski SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:31-5.
PMID: 3569013 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569012
26.
Phase I clinical studies of antineoplaston A3
injections.
Burzynski SR, Kubove E.
Drugs Exp Clin Res. 1987;13 Suppl 1:17-29.
PMID: 3569012 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569011
27.
In vitro cancer growth inhibition and animal
toxicity studies of antineoplaston A3.
Lee SS, Mohabbat MO, Burzynski SR.
Drugs Exp Clin Res. 1987;13 Suppl 1:13-6.
PMID: 3569011 [PubMed - indexed for MEDLINE]
Related citations
Select item 3569010
28.
Initial clinical study with antineoplaston A2
injections in cancer patients with five years' follow-up.
Burzynski SR, Kubove E.
Drugs Exp Clin Res. 1987;13 Suppl 1:1-11.
PMID: 3569010 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743383
29.
Altered methylation complex isozymes as
selective targets for cancer chemotherapy.
Liau MC, Burzynski SR.
Drugs Exp Clin Res. 1986;12 Suppl 1:77-86.
PMID: 3743383 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743382
30.
Chronic animal toxicity studies on
antineoplaston A2.
Burzynski SR, Mohabbat MO.
Drugs Exp Clin Res. 1986;12 Suppl 1:73-5.
PMID: 3743382 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743381
31.
3-Phenylacetylamino-2,6-piperidinedione, a
naturally-occurring peptide analogue with apparent antineoplastic activity, may
bind to DNA.
Lehner AF, Burzynski SR, Hendry LB.
Drugs Exp Clin Res. 1986;12 Suppl 1:57-72.
PMID: 3743381 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743380
32.
Toxicology studies on antineoplaston A10
injections in cancer patients.
Burzynski SR, Kubove E.
Drugs Exp Clin Res. 1986;12 Suppl 1:47-55.
PMID: 3743380 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743379
33.
Preclinical studies on antineoplaston A10
injections.
Ashraf AQ, Liau MC, Mohabbat MO, Burzynski
SR.
Drugs Exp Clin Res. 1986;12 Suppl 1:37-45.
PMID: 3743379 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743378
34.
Toxicology studies on antineoplaston AS2-1
injections in cancer patients.
Burzynski SR, Burzynski B, Mohabbat MO.
Drugs Exp Clin Res. 1986;12 Suppl 1:25-35.
PMID: 3743378 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743377
35.
Toxicology studies on antineoplaston AS2-5
injections in cancer patients.
Burzynski SR.
Drugs Exp Clin Res. 1986;12 Suppl 1:17-24.
PMID: 3743377 [PubMed - indexed for MEDLINE]
Related citations
Select item 3743376
36.
Preclinical studies on antineoplaston AS2-1
and antineoplaston AS2-5.
Burzynski SR, Mohabbat MO, Lee SS.
Drugs Exp Clin Res. 1986;12 Suppl 1:11-6.
PMID: 3743376 [PubMed - indexed for MEDLINE]
Related citations
Select item 3527634
37.
Antineoplastons: history of the research (I).
Burzynski SR.
Drugs Exp Clin Res. 1986;12 Suppl 1:1-9.
Review.
PMID: 3527634 [PubMed - indexed for MEDLINE]
Related citations
Select item 275868
38.
Antineoplaston A in cancer therapy. (I).
Burzynski SR, Stolzmann Z, Szopa B, Stolzmann
E, Kaltenberg OP.
Physiol Chem Phys. 1977;9(6):485-500.
PMID: 275868 [PubMed - indexed for MEDLINE]
Related citations
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.